Targeted proteomics driven verification of biomarker candidates
associated with breast cancer aggressiveness

J 2017

Targeted proteomics driven verification of biomarker candidates associated with breast cancer aggressiveness

PROCHÁZKOVÁ, Iva, Juraj LENČO, Alena FUČÍKOVÁ, Jiří DRESLER, Lenka ČÁPKOVÁ et. al.

Základní údaje

Originální název

Targeted proteomics driven verification of biomarker candidates associated with breast cancer aggressiveness

Autoři

PROCHÁZKOVÁ, Iva (203 Česká republika, domácí), Juraj LENČO (203 Česká republika), Alena FUČÍKOVÁ (203 Česká republika), Jiří DRESLER (203 Česká republika), Lenka ČÁPKOVÁ (203 Česká republika, domácí), Roman HRSTKA (203 Česká republika), Rudolf NENUTIL (203 Česká republika) a Pavel BOUCHAL (203 Česká republika, domácí)

Vydání

Biochimica et Biophysica Acta - Proteins and Proteomics, AMSTERDAM, Elsevier Science, 2017, 1570-9639

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10608 Biochemistry and molecular biology

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.609

Kód RIV

RIV/00216224:14310/17:00095604

Organizační jednotka

Přírodovědecká fakulta

DOI

http://dx.doi.org/10.1016/j.bbapap.2017.02.012

UT WoS

000400714800004

Klíčová slova anglicky

Breast cancer; Selected reaction monitoring; mTRAQ; Estrogen receptor; Tumor grade; Lymph node

Štítky

NZ, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 12. 4. 2018 10:48, Ing. Nicole Zrilić

Anotace

V originále

Breast cancer is the most common and molecularly relatively well characterized malignant disease in women, however, its progression to metastatic cancer remains lethal for 78% of patients 5 years after diagnosis. Novel markers could identify the high risk patients and their verification using quantitative methods is essential to overcome genetic, inter-tumor and intra-tumor variability and translate novel findings into cancer diagnosis and treatment. We recently identified 13 proteins associated with estrogen receptor, tumor grade and lymph node status, the key factors of breast cancer aggressiveness, using untargeted proteomics. Here we verified these findings in the same set of 96 tumors using targeted proteomics based on selected reaction monitoring with mTRAQ labeling (mTRAQ-SRM), transcriptomics and immunohistochemistry and validated in 5 independent sets of 715 patients using transcriptomics. We confirmed: (i) positive association of anterior gradient protein 2 homolog (AGR2) and periostin (POSTN) and negative association of annexin Al (ANXA1) with estrogen receptor status; (ii) positive association of stathmin (STMN1), cofilin-1 (COF1), plasminogen activator inhibitor 1 RNA-binding protein (PAIRBPI) and negative associations of thrombospondin-2 (TSP2) and POSTN levels with tumor grade; and (iii) positive association of POSTN, alpha-actinin-4 (ACTN4) and STMN1 with lymph node status. This study highlights a panel of gene products that can contribute to breast cancer aggressiveness and metastasis, the understanding of which is important for development of more precise breast cancer treatment (C) 2017 Elsevier B.V. All rights reserved.

Návaznosti

GA14-19250S, projekt VaV

Název: Nový panel proteinů korelujících se stavem lymfatických uzlin u low-grade nádorů prsu: Klinická verifikace a úloha v invazivitě nádorových buněk

Investor: Grantová agentura ČR, Nový panel proteinů korelujících se stavem lymfatických uzlin u low-grade nádorů prsu: Klinická verifikace a úloha v invazivitě nádorových buněk

LM2015043, projekt VaV

Název: Česká infrastruktura pro integrativní strukturní biologii (Akronym: CIISB)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Czech Infrastructure for Integrative Structural Biology

Citovat

PROCHÁZKOVÁ, Iva, Juraj LENČO, Alena FUČÍKOVÁ, Jiří DRESLER, Lenka ČÁPKOVÁ, Roman HRSTKA, Rudolf NENUTIL a Pavel BOUCHAL. Targeted proteomics driven verification of biomarker candidates associated with breast cancer aggressiveness. Biochimica et Biophysica Acta - Proteins and Proteomics. AMSTERDAM: Elsevier Science, 2017, roč. 1865, č. 5, s. 488-498. ISSN 1570-9639. Dostupné z: https://dx.doi.org/10.1016/j.bbapap.2017.02.012.

@article{1412658,
   author = {Procházková, Iva and Lenčo, Juraj and Fučíková, Alena and Dresler, Jiří and Čápková, Lenka and Hrstka, Roman and Nenutil, Rudolf and Bouchal, Pavel},
   article_location = {AMSTERDAM},
   article_number = {5},
   doi = {http://dx.doi.org/10.1016/j.bbapap.2017.02.012},
   keywords = {Breast cancer; Selected reaction monitoring; mTRAQ; Estrogen receptor; Tumor grade; Lymph node},
   language = {eng},
   issn = {1570-9639},
   journal = {Biochimica et Biophysica Acta - Proteins and Proteomics},
   title = {Targeted proteomics driven verification of biomarker candidates associated with breast cancer aggressiveness},
   volume = {1865},
   year = {2017}
}

TY  - JOUR
ID  - 1412658
AU  - Procházková, Iva - Lenčo, Juraj - Fučíková, Alena - Dresler, Jiří - Čápková, Lenka - Hrstka, Roman - Nenutil, Rudolf - Bouchal, Pavel
PY  - 2017
TI  - Targeted proteomics driven verification of biomarker candidates associated with breast cancer aggressiveness
JF  - Biochimica et Biophysica Acta - Proteins and Proteomics
VL  - 1865
IS  - 5
SP  - 488-498
EP  - 488-498
PB  - Elsevier Science
SN  - 15709639
KW  - Breast cancer
KW  - Selected reaction monitoring
KW  - mTRAQ
KW  - Estrogen receptor
KW  - Tumor grade
KW  - Lymph node
N2  - Breast cancer is the most common and molecularly relatively well characterized malignant disease in women, however, its progression to metastatic cancer remains lethal for 78% of patients 5 years after diagnosis. Novel markers could identify the high risk patients and their verification using quantitative methods is essential to overcome genetic, inter-tumor and intra-tumor variability and translate novel findings into cancer diagnosis and treatment. We recently identified 13 proteins associated with estrogen receptor, tumor grade and lymph node status, the key factors of breast cancer aggressiveness, using untargeted proteomics. Here we verified these findings in the same set of 96 tumors using targeted proteomics based on selected reaction monitoring with mTRAQ labeling (mTRAQ-SRM), transcriptomics and immunohistochemistry and validated in 5 independent sets of 715 patients using transcriptomics. We confirmed: (i) positive association of anterior gradient protein 2 homolog (AGR2) and periostin (POSTN) and negative association of annexin Al (ANXA1) with estrogen receptor status; (ii) positive association of stathmin (STMN1), cofilin-1 (COF1), plasminogen activator inhibitor 1 RNA-binding protein (PAIRBPI) and negative associations of thrombospondin-2 (TSP2) and POSTN levels with tumor grade; and (iii) positive association of POSTN, alpha-actinin-4 (ACTN4) and STMN1 with lymph node status. This study highlights a panel of gene products that can contribute to breast cancer aggressiveness and metastasis, the understanding of which is important for development of more precise breast cancer treatment (C) 2017 Elsevier B.V. All rights reserved.
ER  -

PROCHÁZKOVÁ, Iva, Juraj LENČO, Alena FUČÍKOVÁ, Jiří DRESLER, Lenka ČÁPKOVÁ, Roman HRSTKA, Rudolf NENUTIL a Pavel BOUCHAL. Targeted proteomics driven verification of biomarker candidates associated with breast cancer aggressiveness. \textit{Biochimica et Biophysica Acta - Proteins and Proteomics}. AMSTERDAM: Elsevier Science, 2017, roč.~1865, č.~5, s.~488-498. ISSN~1570-9639. Dostupné z: https://dx.doi.org/10.1016/j.bbapap.2017.02.012.

Podrobný výpis o publikaci